Here are the 424B prospectus supplements from Apyx Medical Corporation (APYX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow APYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APYX filings page.
Apyx Medical Corporation is conducting a primary offering of 2,762,431 shares of common stock at $3.62 per share, for gross proceeds of about $10,000,000, with an underwriter option for up to 414,365 additional shares. After underwriting fees and estimated expenses, the company expects net proceeds of approximately $9,000,000, which it plans to use for working capital, expanding sales and marketing, capital spending, potential acquisitions and debt repayment.
This financing will increase shares outstanding from 38,251,823 to 41,014,254 (or 41,428,619 if the option is fully exercised) and results in immediate dilution of $3.25 per share to new investors. The filing also highlights recent milestones for the AYON Body Contouring System™, including FDA 510(k) clearance, a soft launch followed by commercial rollout in 2025, and management’s belief that GLP‑1 weight‑loss drug use may ultimately support demand for the company’s Renuvion aesthetic products.
Apyx Medical Corporation plans a primary offering of common stock and pre-funded warrants under its existing Form S-3 shelf registration. Investors may buy either shares or, in lieu of shares, pre-funded warrants that are exercisable for one share of common stock at an exercise price of $0.001 and do not expire, subject to ownership limits.
The company has granted the underwriter a 45-day option to purchase additional common shares. Apyx expects to use the net proceeds for working capital and general corporate purposes, including expanding sales and marketing, capital expenditures, potential acquisitions and debt repayment. Shares outstanding were 37,819,478 as of September 30, 2025.
Apyx is a surgical aesthetics company focused on its Helium Plasma Technology, marketed as Renuvion and the AYON Body Contouring System. It recently received FDA 510(k) clearance for AYON and has begun commercial launch, targeting procedures to address loose or lax skin and other aesthetic treatments.